Zenas BioPharma, Inc. (ZBIO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Zenas BioPharma, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 31.40 $ — 59% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 74.4% passed
- Share count grows by less than 3% a year 5.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -1,623.5% failed
- Gross margin at 40% or higher and without meaningful erosion 100.0% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 263 m net cash passed
- Operating cash flow covers the profits of the last three years 249 m failed
- Return on capital at 15% or higher, or up versus two years ago -65.9% failed
- Insiders hold at least 10% or are net buyers 23.2% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 38.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -4.30 | -5.06 – -3.53 | 36 | 11.1% | 2 |
| 12/31/2027 | -2.27 | -4.34 – -0.19 | 64 | 47.3% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.89 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.26 | – | 5 | – | -1,052.10 | -39 | -39 |
| 2025: Q1 | -0.80 | – | 10 | – | -335.70 | -37 | -37 |
| 2025: Q2 | -1.25 | – | 0 | – | – | -42 | -42 |
| 2025: Q3 | -1.22 | – | 0 | – | – | -41 | -41 |
| 2025: Q4 | -5.17 | – | 10 | 100.00 | -2,404.40 | -52 | -52 |
| 2026: Q1 | -1.46 | – | 0 | -100.00 | – | -75 | -75 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2022 | 0 | -76 | -119 | -3.11 | -66 | -192 | 75 |
| 2023 | 50 | -37 | -37 | -0.97 | -31 | -226 | 68 |
| 2024 | 5 | -164 | -157 | -3.76 | -120 | 312 | 370 |
| 2025 | 10 | -211 | -378 | -8.44 | -172 | 242 | 384 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Zenas BioPharma, Inc. , a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
| Employees | 167 |
|---|---|
| Headquarters | Waltham, MA |
| Address | 852 Winter Street, 02451 Waltham, United States |
| Phone | 857 271 2954 |
| Website | zenasbio.com |
| IPO Date | 13. Sep 2024 |
| ISIN | US98937L1052 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Leon Oliver Moulder Jr., M.B.A. | Founder, CEO & Chairman | 1957 |
| Joseph L. Farmer | COO & President | 1972 |
| Lisa von Moltke M.D. | Head of Research & Development and Chief Medical Officer | 1959 |
| Jennifer A. Fox | Chief Business Officer & CFO | 1972 |
| Heinrich Schlieker Ph.D. | Chief Technical Officer | – |
| Haley Laken Ph.D. | Chief Scientific Officer | – |
| Caroline Chevalier | Chief Administrative Officer | – |
| Jeffrey Held | Chief Legal Officer | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.